Home/Filings/4/0001140361-17-044178
4//SEC Filing

STAPLETON CRAIG R 4

Accession 0001140361-17-044178

CIK 0001012477other

Filed

Nov 28, 7:00 PM ET

Accepted

Nov 29, 4:35 PM ET

Size

13.2 KB

Accession

0001140361-17-044178

Insider Transaction Report

Form 4
Period: 2017-11-27
Transactions
  • Sale

    ADSs

    2017-11-27$9.35/sh254,265$2,377,632253,413 total
Holdings
  • Warrants (right to buy)

    Exercise: $21.67From: 2016-06-26Exp: 2019-06-26ADSs (117,449 underlying)
    117,449
  • ADSs

    (indirect: By Spouse)
    110,000
  • Warrants (right to buy)

    Exercise: $14.54From: 2015-06-24Exp: 2018-06-24ADSs (100,000 underlying)
    100,000
  • Warrants (right to buy)

    Exercise: $13.59From: 2017-08-10Exp: 2020-08-10ADSs (117,449 underlying)
    117,449
  • Stock Option (right to buy)

    Exercise: $10.51From: 2018-06-28Exp: 2022-06-28ADSs (30,000 underlying)
    30,000
Footnotes (7)
  • [F1]The issuer's "ADSs" are American Depositary Shares, with each ADS representing one ordinary share, nominal value $0.01 per share, of the issuer; ADSs may be represented by American Depositary Receipts.
  • [F2]Reflects the transfer of ADSs of the issuer by the reporting person to a trust of which the trustees are two adult children of the reporting person who do not live in the reporting person's household. In consideration for the transfer of these ADSs, the trust gave the reporting person property with an aggregate value approximately equal to the market value of the transferred ADSs on the date of the transfer.
  • [F3]The filing of this statement shall not be construed as an admission that the reporting person is, for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise, the beneficial owner of these securities.
  • [F4]Warrants were granted 06/24/2014 but were not exercisable until the first anniversary of the date of grant; on such first anniversary the warrants became exercisable for a 3-year period as to all 100,000 ADSs. The warrant exercise price per ADS may be paid in U.S. Dollars as shown in Item 4 of Table II or in Euros based on the exchange rate prevailing on the date of grant, or (euro)10.94 per ADS.
  • [F5]Warrants were granted 06/26/2015 but were not exercisable until the first anniversary of the date of grant; on such first anniversary the warrants became exercisable for a 3-year period as to all 117,449 ADSs. The warrant exercise price per ADS may be paid in U.S. Dollars as shown in Item 4 of Table II or in Euros based on the exchange rate prevailing on the date of grant, or (euro)19.34 per ADS.
  • [F6]Warrants were granted 08/10/2016 but were not exercisable until the first anniversary of the date of grant; on such first anniversary the warrants became exercisable for a 3-year period as to all 117,449 ADSs. The warrant exercise price per ADS may be paid in U.S. Dollars as shown in Item 4 of Table II or in Euros based on the exchange rate prevailing on the date of grant, or (euro) 12.16 per ADS. Warrants as to all 117,449 ADSs vested on 08/10/2017.
  • [F7]Options become exercisable as to all 30,000 ADSs on the first anniversary of the 06/28/2017 grant date.

Documents

1 file

Issuer

AVADEL PHARMACEUTICALS PLC

CIK 0001012477

Entity typeother

Related Parties

1
  • filerCIK 0001207106

Filing Metadata

Form type
4
Filed
Nov 28, 7:00 PM ET
Accepted
Nov 29, 4:35 PM ET
Size
13.2 KB